Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 4/20 | 0.74 |
| ▸ | MAPT | P10636 | 3/20 | 0.74 |
| ▸ | LMNA | P02545 | 2/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.74 |
| ▸ | NCOA1 | Q15788 | 2/20 | 0.71 |
| ▸ | NCOA3 | Q9Y6Q9 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | CD38 | P28907 | 1/20 | 0.58 |
| ▸ | EGFR | P00533 | 5/20 | 0.58 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.58 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.56 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28469603 | 0.91 | MAPK1 (0.65) | HTTMAPTLMNASMN1; SMN2MAPK1 | |
| SCHEMBL5564480 | 0.87 | MAPK1 (0.76) | HTTMAPTLMNASMN1; SMN2MAPK1 | |
| SCHEMBL5568874 | 0.85 | HTT (0.74) | HTTMAPTLMNASMN1; SMN2MAPK1 | |
| SCHEMBL5568430 | 0.85 | HTT (1.00) | HTTMAPTLMNASMN1; SMN2MAPK1 | |
| SCHEMBL5569927 | 0.85 | KDM4E (0.74) | HTTMAPTLMNASMN1; SMN2MAPK1 | |
| SCHEMBL2101381 | 0.85 | HTT (1.00) | HTTMAPTLMNASMN1; SMN2MAPK1 | |
| SCHEMBL5570076 | 0.83 | HTT (0.70) | HTTMAPTLMNASMN1; SMN2MAPK1 | |
| SCHEMBL15503743 | 0.83 | NCOA1 (1.00) | HTTMAPTLMNASMN1; SMN2MAPK1 | |
| SCHEMBL5564605 | 0.82 | MAPK1 (0.68) | HTTMAPTLMNASMN1; SMN2MAPK1 | |
| SCHEMBL6668474 | 0.82 | HTT (0.68) | HTTMAPTLMNASMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | GPC BIOTECH AG (DE) | 2007-05-31 | — | — | US | claimed |
| EP-1673346-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC Biotech AG (DE) | 2006-06-28 | — | — | EP | claimed |
| WO-2005040125-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC BIOTECH AG (DE) | 2005-05-06 | — | — | WO | claimed |
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | GPC BIOTECH AG (DE) | 2007-05-31 | — | — | US | disclosed |
| EP-1673346-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC Biotech AG (DE) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005040125-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC BIOTECH AG (DE) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | IRF3, PML, TPMT | HTT 2700/4885MAPT 555/4885LMNA 4258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.